Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8+ T cells. (3rd August 2017)

• Record Type: Journal Article
• Authors: Hanoteau, Aurélie; Henin, Coralie; Svec, David; Bisilliat Donnet, Charlotte; Denanglaire, Sébastien; Colau, Didier; Romero, Pedro; Leo, Oberdan; Van den Eynde, Benoit; Moser, Muriel
• Is Part Of: Oncoimmunology. Volume 6:Number 8(2017)
• Publication Date: 2017-08-03
• Subjects: CD8+ T cells -- cyclophosphamide -- effector function -- exhaustion -- tumor-specific immunity; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2017.1318234
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: An important question is how chemotherapy may (re-)activate tumor-specific immunity. In this study, we provide a phenotypic, functional and genomic analysis of tumor-specific CD8 + T cells in tumor (P815)-bearing mice, treated or not with cyclophosphamide. Our data show that chemotherapy favors the development of effector-type lymphocytes in tumor bed, characterized by higher KLRG-1 expression, lower PD-1 expression and increased cytotoxicity. This suggests re-engagement of T lymphocytes into the effector program. IFN-I appears involved in this remodeling. Our findings provide some insight into how cyclophosphamide regulates the amplitude and quality of tumor-specific immune responses.